Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.
Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.
Efavirenz (Sustiva, Stocrin) use was associated with a 60% increased risk of neurological conditions in children, according to data presented at IDWeek 2018 in San Francisco.
Drug-drug interactions and side effects, associated with currently-used first-line antiretroviral therapy, are under-reported and managed in Uganda.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.
Although central nervous system side effects associated with efavirenz have led to newer drugs being recommended in in high income countries, WHO guidelines for low and middle income countries still recommend efavirenz for first-line therapy.
Researchers set out to find a way for HIV-positive people to continue using efavirenz (Sustiva, Stocrin) at lower doses in an effort to reduce severe side effects.